Clinical Trial Update: Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluating a nanobody-based tandem CD19/CD20 CAR-T-cell therapy for relapsed or refractory B-cell lymphoma; the trial is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy

Snippet

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences | Conditions: Relapsed/Refractory B-Cell Lymphoma | EARLY_Phase 1 | Status: NOT_YET_RECRUITING